Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer

Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study

(2018) Rahul Aggarwal et al.   JOURNAL OF CLINICAL ONCOLOGY

Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling

(2018) Pernilla Roswall et al.   NATURE MEDICINE

FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate

(2017) Jung Wook Park et al.   MODERN PATHOLOGY

SOX2 promotes lineage plasticity and antiandrogen resistance in TP53 - and RB1 -deficient prostate cancer

(2017) Ping Mu et al.   SCIENCE

Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases

(2017) Helen Ha et al.   Theranostics

N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells

(2016) John K. Lee et al.   CANCER CELL

Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer

(2016) Himisha Beltran et al.   NATURE MEDICINE

Organoid culture systems for prostate epithelial and cancer tissue

(2016) Jarno Drost et al.   Nature Protocols

Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer

(2016) Tanya Stoyanova et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay

(2016) Jung Wook Park et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer

(2015) C. Liu et al.   CANCER RESEARCH

Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer

(2015) Michael D. Brooks et al.   Cell Stem Cell

A basal stem cell signature identifies aggressive prostate cancer phenotypes

(2015) Bryan A. Smith et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cancer treatment and survivorship statistics, 2014

(2014) Carol E. DeSantis et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer

(2014) Z. Chen et al.   EMBO JOURNAL

Emerging mechanisms of enzalutamide resistance in prostate cancer

(2014) Frank Claessens et al.   Nature Reviews Urology

Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer

(2014) Dayong Wu et al.   NUCLEIC ACIDS RESEARCH

The Many Faces of Neuroendocrine Differentiation in Prostate Cancer Progression

(2014) Stéphane Terry et al.   Frontiers in Oncology

Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial

(2012) P. Nair et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Purification and direct transformation of epithelial progenitor cells from primary human prostate

(2011) Andrew S Goldstein et al.   Nature Protocols

Abiraterone and Increased Survival in Metastatic Prostate Cancer

(2011) Johann S. de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

PC3 is a cell line characteristic of prostatic small cell carcinoma

(2011) Sheng Tai et al.   PROSTATE

Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets

(2011) H. Beltran et al.   Cancer Discovery

Integrative Genomic Profiling of Human Prostate Cancer

(2010) Barry S. Taylor et al.   CANCER CELL

Identification of a Cell of Origin for Human Prostate Cancer

(2010) A. S. Goldstein et al.   SCIENCE

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

(2009) David A. Barbie et al.   NATURE

CXCR2 antagonists for the treatment of pulmonary disease

(2008) R.W. Chapman et al.   PHARMACOLOGY & THERAPEUTICS